Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study

Autor: Hélène Kuyas, Muh Hwa Yang, Winson Y. Cheung, Valérie Auclair, Roshani Shah, Viktor Grünwald, Myung-Ju Ahn, Katrin Marie Sjoquist, Xavier Guillaume, Alfonso Berrocal, Kevin J. Harrington, S. Joo, Diana Chirovsky, Gilberto de Castro, Federica Bertolini
Rok vydání: 2020
Předmět:
Bridged-Ring Compounds
Male
Canada
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Taiwan
Medizin
Cetuximab
Platinum Compounds
Kaplan-Meier Estimate
Systemic therapy
03 medical and health sciences
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Republic of Korea
Confidence Intervals
medicine
Humans
030223 otorhinolaryngology
Survival analysis
Aged
Retrospective Studies
Chemotherapy
Squamous Cell Carcinoma of Head and Neck
business.industry
Head and neck cancer
Australia
Middle Aged
medicine.disease
Head and neck squamous-cell carcinoma
Confidence interval
Europe
Regimen
Methotrexate
Treatment Outcome
Oncology
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Female
Taxoids
Fluorouracil
Neoplasm Recurrence
Local
Oral Surgery
business
Brazil
medicine.drug
Zdroj: Oral Oncology. 102:104526
ISSN: 1368-8375
DOI: 10.1016/j.oraloncology.2019.104526
Popis: Objectives Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting. Materials and methods A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characteristics, treatment and survival data. Results Among 733 R/M HNSCC patients across 71 sites, median age was 60 years (inter-quartile range 54–67), 84% male, and 70% Eastern Cooperative Oncology Group performance status 0–1; 32% had oral cavity and 30% oropharyngeal cancers. The most common first-line regimen across all countries consisted of platinum-based combinations (73%), including platinum + 5-fluorouracil (5-FU) (26%), cetuximab + platinum ± 5-FU (22%), or taxane + platinum ± 5-FU (16%). However, use of different platinum-based combinations varied substantially; administration of cetuximab + platinum ± 5-FU was frequent in Italy (81%), Germany (46%) and Spain (38%), whereas use in other countries was limited. Median follow-up was 22.6 months (95% confidence interval [CI]: 21.5–24.6 months). Median real-world overall survival was only 8.0 months (95% CI: 7.0–8.0), with one-year survival reaching only 30.9% (95% CI: 27.5–34.3). Conclusion Systemic therapies used in clinical practice for patients with R/M HNSCC vary substantially across countries. Prognosis remains poor in this patient population, highlighting the need for newer, more efficacious treatments.
Databáze: OpenAIRE
Externí odkaz: